Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Industry News

Corvia Medical Announces Randomization of First Patient in the RESPONDER-HF Confirmatory Trial

December 06, 2022

News Industry News

preCARDIA Enrolls First Patient in Early Feasibility Study

August 15, 2019

News Industry News

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

October 27, 2015

News Industry News

Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are Maintained After 12 Months

September 28, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Industry News

Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696

August 11, 2014

News Industry News

Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure

May 23, 2014

News Industry News

Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session

March 27, 2014

News Industry News

Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial

September 29, 2011

Advertisement

Corvia Medical Announces Randomization of First Patient in the RESPONDER-HF Confirmatory Trial

preCARDIA Enrolls First Patient in Early Feasibility Study

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are Maintained After 12 Months

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696

Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure

Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session

Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content